Biotech News

Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain

Organogenesis (ORGO)OrganogenesisFDA / regulatory

Clinical Development Program Appropriate for Rolling BLA Submission Expected by the End of 2025 CANTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of

Related news

Organogenesis

Regenerative Medicine Organogenesis develops and manufactures regenerative-medicine products used to support healing in difficult wounds and surgical procedures. Advanced Wound Care The company's wound-care portfolio includes cellular and tissue-based products, placental-derived products and other biologic matrices used in chronic and...

Recent company news

Stock data

Close
2.41 USD
Market cap
288.23M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States